Search research articles
Contact Us
Filters
Showing results (21-30 of 73) with videos related to
Page
of 8
Sort By:
BMC Rheumatology
|
May 16, 2024
Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany
Michael Schultze, Elena Garal-Pantaler, Marc Pignot, et al.
Autoimmunity Reviews
|
June 10, 2018
Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis
Md Asiful Islam, Fahmida Alam, Cinzia Cavestro, et al.
Journal of Health Economics and Outcomes Research
|
August 22, 2023
Development of a Conceptual Model to Understand Disease Burden in Patients With Systemic Lupus Erythematosus and Organ Damage
Lynne Broderick, Wen-Hung Chen, Roger A Levy, et al.
Lupus
|
March 2, 2026
Long-term steroid-sparing effect of belimumab in systemic lupus erythematosus: Post hoc pooled analysis of OBSErve multi-country cohort data
Daniel Moldaver, Seth Anderson, Marguerite Bracher, et al.
Kidney International
|
May 22, 2026
A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis
Richard Furie, Hans-Joachim Anders, George Bertsias, et al.
Lupus Science & Medicine
|
April 5, 2023
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
Kenei Sada, Noriaki Kurita, Hisashi Noma, et al.
Revista Brasileira De Reumatologia
|
October 4, 2016
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center
Verônica Silva Vilela, Giselle Baptista Maretti, Lívia Marques da Silva Gama, et al.
Annals of the Rheumatic Diseases
|
March 26, 2013
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
Vibeke Strand, Roger A Levy, Ricard Cervera, et al.
Rheumatology International
|
October 6, 2006
Primary antiphospholipid nephropathy beginning during pregnancy
Evandro M Klumb, Maria Celia de Andrade, Nilson R Jesús, et al.
Arthritis and Rheumatism
|
June 12, 2013
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
Michelle A Petri, Ronald F van Vollenhoven, Jill Buyon, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 73) with videos related to
Sort By:
Page
of 8
BMC Rheumatology
|
May 16, 2024
Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany
Michael Schultze, Elena Garal-Pantaler, Marc Pignot, et al.
Autoimmunity Reviews
|
June 10, 2018
Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis
Md Asiful Islam, Fahmida Alam, Cinzia Cavestro, et al.
Journal of Health Economics and Outcomes Research
|
August 22, 2023
Development of a Conceptual Model to Understand Disease Burden in Patients With Systemic Lupus Erythematosus and Organ Damage
Lynne Broderick, Wen-Hung Chen, Roger A Levy, et al.
Lupus
|
March 2, 2026
Long-term steroid-sparing effect of belimumab in systemic lupus erythematosus: Post hoc pooled analysis of OBSErve multi-country cohort data
Daniel Moldaver, Seth Anderson, Marguerite Bracher, et al.
Kidney International
|
May 22, 2026
A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis
Richard Furie, Hans-Joachim Anders, George Bertsias, et al.
Lupus Science & Medicine
|
April 5, 2023
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
Kenei Sada, Noriaki Kurita, Hisashi Noma, et al.
Revista Brasileira De Reumatologia
|
October 4, 2016
Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center
Verônica Silva Vilela, Giselle Baptista Maretti, Lívia Marques da Silva Gama, et al.
Annals of the Rheumatic Diseases
|
March 26, 2013
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
Vibeke Strand, Roger A Levy, Ricard Cervera, et al.
Rheumatology International
|
October 6, 2006
Primary antiphospholipid nephropathy beginning during pregnancy
Evandro M Klumb, Maria Celia de Andrade, Nilson R Jesús, et al.
Arthritis and Rheumatism
|
June 12, 2013
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials
Michelle A Petri, Ronald F van Vollenhoven, Jill Buyon, et al.
Page
of 8